News

Bictegravir is one of the three drugs used in Biktarvy, which secured approval from the US Food and Drug Administration (FDA) for the treatment of human immunodeficiency virus type

Bexsero is the first vaccine in the world to receive the Breakthrough Therapy Designation (BTD) twice. In 2014, Bexsero received BTD for development in the prevention of IMD

The companies have signed a global co-development and commercialization agreement that could generate up to $1bn for Theravance. Theravance's TD-1473 is an internally-discovered Janus kinase (JAK) inhibitor that has demonstrated

AstraZeneca announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV death, myocardial infarction,

The approval for Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) supported by data from four ongoing phase 3 trials. Biktarvy combines bictegravir, an integrase strand transfer inhibitor, with

FDA Breakthrough Therapy Designation is intended to expedite the development and review of medicines aimed at treating a serious or life-threatening disease where there is preliminary clinical evidence

Under the terms of the agreement, DL Medicine will screen and collaborate with Pfizer in producing new chemical entities against pre-selected targets from multiple therapeutic areas. As part

The trial, dubbed IMmotion151, met its co-primary endpoint of progression-free survival (PFS) in patients whose metastatic renal cell carcinoma (mRCC) expressed the PD-L1 protein. In the study, the

During the mid-20th century, multiple chemical compounds with antibacterial properties were analyzed, of which few have been used for development into drugs. By using advanced science and technology, scientists